Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Polaris Venture Management Co. V, L.L.C. (CIK 1439589) reported $14.1M across 6 reported positions in its SEC 13F filing for 2021-09-30. Largest positions: LYRA ($10.0M, 71.28%), XFOR ($1.6M, 11.70%), LIFE ($1.2M, 8.42%), DARE ($545,000, 3.87%), GNCA ($379,000, 2.69%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | LYRA | Lyra Therapeutics, Inc. | $10.0M | 71.28% | 1.1M | Hold |
| 2 | XFOR | x4 Pharmaceuticals Inc. | $1.6M | 11.70% | 311,492 | Hold |
| 3 | LIFE | Atyr Pharma Inc. | $1.2M | 8.42% | 130,572 | Hold |
| 4 | DARE | Dare Bioscience, Inc. | $545,000 | 3.87% | 326,240 | Hold |
| 5 | GNCA | Genocea Biosciences, Inc. | $379,000 | 2.69% | 197,345 | Hold |
| 6 | PULM | Pulmatrix, Inc. | $288,000 | 2.04% | 359,441 | Hold |
| 7 | FATE | Fate Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2021-09-30